Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents

Pablo Binder, Theoni Katopodi, Lyndsey Hanson, Charlotte R. Bell, Eimear Flanagan, Paul Farrington, Nick Moore, Emily Wright, Yin Xin Ho, Tobias Bunday, Stewart Brown, Amy Cantrell, Yael Mamane, Jon Greenall, Shannon Sharman, John Woolley, Lorraine M. Mooney, Jane Kendrew

Mol Cancer Ther (2024) 23 (6_Supplement): A004.

https://doi.org/10.1158/1538-8514.SYNTHLETH24-A004

Published: 10 June 2024

View articletitled, Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents

Journal Articles

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS^G12C Inhibition in KRAS^G12C-mutant Colorectal Cancer

Hajrah Khawaja, Rebecca Briggs, Cheryl H. Latimer, Mustasin Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Frederica Di Nicolantonio, Simon S. McDade, Christopher J. Scott, Shauna Lambe, Manisha Maurya, Andreas U. Lindner, Jochen H.M. Prehn, Jose Sousa, Chris Winnington, Melissa J. LaBonte, Sarah Ross, Sandra Van Schaeybroeck

Mol Cancer Ther (2023) 22 (1): 135–149.

https://doi.org/10.1158/1535-7163.MCT-22-0301

Published: 03 January 2023

View articletitled, Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer

Includes: Supplementary data

Journal Articles

AZD4625 is a Potent and Selective Inhibitor of KRAS^G12C

Mol Cancer Ther (2022) 21 (10): 1535–1546.

https://doi.org/10.1158/1535-7163.MCT-22-0241

Published: 07 October 2022

View articletitled, AZD4625 is a Potent and Selective Inhibitor of KRASG12C

Includes: Supplementary data

Journal Articles

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Mol Cancer Ther (2021) 20 (2): 238–249.

https://doi.org/10.1158/1535-7163.MCT-20-0002

Published: 05 February 2021

View articletitled, AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Includes: Supplementary data

Journal Articles

Abstract B156: Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor

Vikki Flemington, Iain Simpson, Emma Davies, David Robinson, Nicola Lindsay, Lyndsey Hanson, Philip Hopcroft, Michael Tonge, Karen Roberts, Richard Ward

Mol Cancer Ther (2018) 17 (1_Supplement): B156.

https://doi.org/10.1158/1535-7163.TARG-17-B156

Published: 01 January 2018

View articletitled, Abstract B156: Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor

Journal Articles

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Kevin Hudson, Urs J. Hancox, Cath Trigwell, Robert McEwen, Urszula M. Polanska, Myria Nikolaou, Pablo Morentin Gutierrez, Alvaro Avivar-Valderas, Oona Delpuech, Phillippa Dudley, Lyndsey Hanson, Rebecca Ellston, Alys Jones, Marie Cumberbatch, Sabina C. Cosulich, Lara Ward, Francisco Cruzalegui, Stephen Green

Mol Cancer Ther (2016) 15 (5): 877–889.

https://doi.org/10.1158/1535-7163.MCT-15-0687

Published: 05 May 2016

View articletitled, Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Includes: Supplementary data

Journal Articles

Tumors with AKT1^E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D'Cruz, Michael Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, Emma L. Jenkins

Mol Cancer Ther (2015) 14 (11): 2441–2451.

https://doi.org/10.1158/1535-7163.MCT-15-0230

Published: 03 November 2015

View articletitled, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Includes: Supplementary data

Journal Articles

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Mol Cancer Ther (2015) 14 (1): 48–58.

https://doi.org/10.1158/1535-7163.MCT-14-0406

Published: 13 January 2015

View articletitled, Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS^G12C Inhibition in KRAS^G12C-mutant Colorectal Cancer

AZD4625 is a Potent and Selective Inhibitor of KRAS^G12C

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Abstract B156: Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Tumors with AKT1^E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only